In recent years, non-IgG antibodies exhibit certain therapeutic advantages over widely applied IgG monoclonal antibodies in tumors, infections, and inflammation. To further investigate and offer better services for non-IgG antibodies, Creative Biolabs has specially constructed a professional platform to provide non-IgG antibody production and purification services for customers in need.
Our Service
IgM Production
Creative Biolabs utilizes both recombinant and hybridoma-based platforms for versatile IgM antibody production, accommodating diverse research needs across multiple species. Our advanced expression system platform is based on several high-performance cell lines:
- CHO (Chinese Hamster Ovary) Cells - Ideal for large-scale IgM antibody production with high yield and stability.
- HEK293 Cells - Well-suited for human-specific IgM production.
- PER.C6 and Myeloma Cell Lines - Additional robust cell lines for stable IgM antibody expression.
The process includes gene synthesis, vector construction, plasmid preparation, and transient transfection or stable cell line development. This workflow produces IgM in pentameric or hexameric forms with appropriate disulfide bonding and J-chain formation, ensuring structural integrity and functional efficacy. We also provide traditional hybridoma technology options, including human-human and hetero-hybridomas, for reliable IgM production.
IgM Purification
Purification of IgM presents unique challenges due to its structural complexity and large molecular size, which renders typical protein A/G affinity chromatography ineffective. To address this, Creative Biolabs offers advanced purification strategies tailored for IgM:
-
Three-Step Strategy (CHT/AIX/CIX):
This method starts with ceramic hydroxyapatite (CHT) enrichment, followed by anion (AIX) and cation (CIX) exchange steps, achieving up to 99% purity with recovery rates of 51%-80%. -
Two-Step Strategy (PEG/AIX):
Combining PEG precipitation with anion exchange, this method is optimized for hybridoma supernatants, yielding 96% purity and a recovery rate range of 28%-84%. -
Size Exclusion Chromatography (SXC):
SXC leverages steric exclusion using a hydrophilic matrix and PEG, yielding 90% purity and 90% recovery. This method is particularly efficient for high-throughput applications. -
Capture Select Method:
Employing llama antibody fragments that target human IgM μ-chains, this technique uses sepharose beads to isolate IgM with high specificity, ideal for clinical-grade applications.
Fig.1 A process of our
IgM production and purification.
Highlights
-
Flexible Production Platforms
Offering both recombinant and hybridoma-based IgM production systems tailored to diverse research requirements and species specificity. -
Comprehensive Purification Options
Multiple advanced IgM purification strategies, including three-step ion exchange and size exclusion chromatography, ensure high purity and yield. -
High-Specificity Capture Select Method
Utilizes llama antibody fragments specific to the human IgM μ-chain, ideal for clinical-grade applications with enhanced purity. -
Optimized Recovery Rates
Custom purification methods with carefully optimized recovery rates to maintain high antibody yield for both research and therapeutic applications. -
Robust Host Cell Line
Employs high-yield cell lines like CHO, HEK293, and PER.C6 to ensure consistent IgM production at various scales. -
Scalability and Consistency
Capable of scaling up production while maintaining consistency in IgM structure, yield, and quality, suitable for both preclinical and clinical studies. -
Non-IgG Specialization
Expertise extends beyond IgG, covering IgM, IgA, IgE, and IgY antibodies to meet diverse research and therapeutic demands. -
Expert Technical Support
Backed by a dedicated team of scientists who offer tailored solutions and ongoing support for unique project needs in IgM antibody production and purification.
Background
IgM is the earliest antibody class expressed in the human fetus, and it is also the major isotype produced at the early stage in the primary response to antigens. In general, IgMs are produced by the immune system and play an important role in both innate and adaptive humoral immune responses. Just similar to other types of antibody molecules, IgM monomeric molecular consists of two identical heavy chains (μ) and two light chains (κ or λ). The predominant form of IgM in human serum is pentamer (~950 kDa) which is composed of five monomers connected with the joining-(J) chain. The other forms, such as hexamers (~1100kDa) and monomers (~170kDa), can also be found at rather a low abundance in vivo.
As an alternative therapeutic agent for IgG, IgM therapy benefits from the superior mobilization of effector functions. It has been found that IgM in pentameric form is the most efficient in the classical pathway of complement system activation. What's more, mucosal immunity can be attained by the transfer of IgM through the epithelial barrier. Besides the immune protective effect, IgM antibody exhibits great therapeutic potential in the treatment of various tumors both in laboratory and clinical research. Therefore, a large amount of high-quality IgM is necessary for pre-clinical and clinical testing.
Fig. 2 Structure of (A) IgG; (B) pentameric
IgM; and (C) hexameric IgM.1
FAQs
Q1: What IgM production platforms are available at Creative Biolabs?
A: Creative Biolabs offers both recombinant and hybridoma-based IgM production systems. Recombinant production utilizes cell lines such as CHO, HEK293, and PER.C6, enabling high-yield, species-specific IgM production. Hybridoma-based systems include traditional and human-human hybridomas, allowing for diverse options tailored to research needs.
Q2: What are the purification options for IgM antibodies?
A: Creative Biolabs provides several advanced IgM purification methods, including a three-step ion exchange strategy, a two-step PEG-based approach, size exclusion chromatography (SXC), and the Capture Select method. Each method is optimized for high purity and recovery rates suited for different applications, including clinical-grade IgM.
Q3: Why is IgM purification challenging, and how does Creative Biolabs address this?
A: IgM purification is complex due to its large molecular size and structure, making conventional protein A/G affinity chromatography ineffective. Creative Biolabs uses specialized methods such as ceramic hydroxyapatite enrichment, PEG precipitation, and Capture Select to achieve high purity and recovery, ensuring the IgM retains its functional integrity.
Q4: How does Creative Biolabs ensure structural integrity in IgM production?
A: Creative Biolabs ensures structural integrity in IgM antibodies by incorporating disulfide bonding and J-chain formation during production. This approach yields pentameric or hexameric forms with complete structural and functional efficacy, which is essential for therapeutic and research applications.
Q5: What therapeutic advantages does IgM offer compared to IgG?
A: IgM demonstrates superior mobilization of effector functions, particularly in classical complement pathway activation, and can achieve mucosal immunity through epithelial barrier transfer.
Resource
A Brief Introduction to Non-IgG Antibody - Creative Biolabs 
A Brief Introduction to Non-IgG Antibody -
Creative Biolabs
Based on our comprehensive antibody platforms and professional experts, Creative Biolabs has absolute advantages in providing non-IgG antibody production and purification services. Additionally, our ready-made/custom non-IgG antibody products and related services will help you achieve milestone development. Just directly contact us if you are interested, and our scientist will customize the most suitable solutions for your programs.
Quotation and Ordering
Our customer service representatives are available 24/7/365. You may contact us anytime for assistance. Orders can be placed online, over the phone, by email, or by fax.
Reference
- Mader, Alexander, et al. "Recombinant IgM expression in mammalian cells: A target protein challenging biotechnological production." Advances in Bioscience and Biotechnology 4 (2013):38-43. Distributed under open access license CC BY 4.0, without modification.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
